mobilized外周血干细胞与未刺激骨髓作为T细胞充足单倍体移植后环磷酰胺方案移植物来源的比较
该研究比较了2009至2014年间美国681例血液恶性肿瘤患者接受骨髓(n=481)或外周血(n=190)单倍体移植后的结局。两组造血恢复相似,但骨髓移植的2-4级急性移植物抗宿主病(GVHD)和慢性GVHD风险更低;总生存无显著差异,骨髓移植复发风险更高(仅白血病亚组)。作者认为两种移植物均适用,但失败模式不同,需随机前瞻性研究验证。
要点
- 骨髓与外周血移植后28天中性粒细胞恢复率分别为88%和93%(P=.07),100天血小板恢复率分别为88%和85%(P=.33)。
- 骨髓移植的2-4级急性GVHD风险低于外周血(HR 0.45,P<.001),慢性GVHD风险也更低(HR 0.35,P<.001)。
- 总生存无显著差异(HR 0.99,P=.98),2年生存率骨髓组54%、外周血组57%;骨髓移植复发风险更高(HR 1.49,P=.009),仅限白血病患者(HR 1.73,P=.002)。
核心结论
- 外周血和骨髓移植物均适用于采用移植后环磷酰胺方案的单倍体移植,但治疗失败模式不同。
- 作者认为这是目前最全面的比较,但 findings 需在充分随访的随机前瞻性比较中验证。
研究设计与样本
- 研究纳入2009至2014年在美国接受移植的681例血液恶性肿瘤患者,其中骨髓移植481例,外周血移植190例。
- 采用Cox回归模型分析移植物类型对移植结局的影响,并校正患者、疾病和移植特征。
主要发现
- 造血恢复:28天中性粒细胞恢复率骨髓组88% vs 外周血组93%(P=.07);100天血小板恢复率骨髓组88% vs 外周血组85%(P=.33)。
- 2-4级急性GVHD风险骨髓组低于外周血组(HR 0.45,P<.001);慢性GVHD风险骨髓组也低于外周血组(HR 0.35,P<.001)。
- 总生存无显著差异(HR 0.99,P=.98),2年生存率骨髓组54% vs 外周血组57%。
- 非复发死亡风险无差异(HR 0.92,P=.74);复发风险骨髓组高于外周血组(HR 1.49,P=.009)。
- 进一步分析显示,骨髓移植后更高的复发风险仅限于白血病患者(HR 1.73,P=.002),淋巴瘤患者无显著差异(HR 0.87,P=.64)。
临床怎么用
- 原文结论认为外周血和骨髓移植物均适用于采用移植后环磷酰胺方案的单倍体移植,但治疗失败模式不同。
- 原文未据此给出具体的临床推荐。
局限性
- 原文指出这些发现必须在充分随访的随机前瞻性比较中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose T-cell-replete HLA-haploidentical donor hematopoietic transplantation using post-transplant cyclophosphamide was originally described using bone marrow (BM). With increasing use of mobilized peripheral blood (PB), we compared transplant outcomes after PB and BM transplants. Patients and Methods A total of 681 patients with hematologic malignancy who underwent transplantation in the United States between 2009 and 2014 received BM (n = 481) or PB (n = 190) grafts. Cox regression models were built to examine differences in transplant outcomes by graft type, adjusting for patient, disease, and transplant characteristics. Results Hematopoietic recovery was similar after transplantation of BM and PB (28-day neutrophil recovery, 88% v 93%, P = .07; 100-day platelet recovery, 88% v 85%, P = .33). Risks of grade 2 to 4 acute (hazard ratio [HR], 0.45; P < .001) and chronic (HR, 0.35; P < .001) graft-versus-host disease were lower with transplantation of BM compared with PB. There were no significant differences in overall survival by graft type (HR, 0.99; P = .98), with rates of 54% and 57% at 2 years after transplantation of BM and PB, respectively. There were no differences in nonrelapse mortality risks (HR, 0.92; P = .74) but relapse risks were higher after transplantation of BM (HR, 1.49; P = .009). Additional exploration confirmed that the higher relapse risks after transplantation of BM were limited to patients with leukemia (HR, 1.73; P = .002) and not lymphoma (HR, 0.87; P = .64). Conclusion PB and BM grafts are suitable for haploidentical transplantation with the post-transplant cyclophosphamide approach but with differing patterns of treatment failure. Although, to our knowledge, this is the most comprehensive comparison, these findings must be validated in a randomized prospective comparison with adequate follow-up.
引用
- Bashey A, Zhang MJ, McCurdy SR, et al. Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017. PMID: 28644773. doi:10.1200/JCO.2017.72.8428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。